This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Individuals with high levels of antibodies to the Epstein–Barr virus nuclear antigen 1 (EBNA-1) have an increased risk of developing multiple sclerosis (MS), but this association could be confounded by genetic susceptibility.
Methods: We conducted a nested case-control study including 148 women with MS (18 with blood collected before disease onset) and 296 age-matched healthy women to determine whether the human leukocyte antigen (HLA) DRB1*1501 allele (DR15) and anti-Epstein–Barr virus (anti-EBV) antibody titers are independent risk factors for MS.
Results: The association between anti-EBNA-1 antibody titers and MS risk was not affected by adjustment for DR15 and was similar in DR15-positive and DR15-negative women. The relative risk of MS among DR15-positive women with elevated (>1:320) anti-EBNA-1 titers was ninefold higher than that of DR15-negative women with low (<1:80) anti-EBNA-1 titers.
Conclusions: Anti-Epstein–Barr virus nuclear antigen 1 (anti-EBNA-1) antibody titers are a risk factor for multiple sclerosis (MS), independently from the DR15 allele. Carriers of the DR15 allele with elevated anti-EBNA-1 antibody titers may have a markedly increased risk of MS.
GLOSSARY: CMV = cytomegalovirus; EBV = Epstein–Barr virus; HLA = human leukocyte antigen; MS = multiple sclerosis; NHS = Nurses' Health Study; RR = relative risk.
Footnotes
-
Editorial, page 1067
e-Pub ahead of print on February 13, 2008, at www.neurology.org.
Supported by NIH–National Institute of Neurological Disorders and Stroke Grant R01 NS47467 (A.A.). P.L.D.J. is the William C. Fowler scholar in Multiple Sclerosis and is supported by NIH–National Institute of Neurological Disorders and Stroke Grant K08. J.D.R. is supported by grants from the NIH–National Institute of Diabetes and Digestive and Kidney Diseases and NIH–National Institute of Allergy and Infectious Diseases.
Disclosure: The authors report no conflicts of interest.
Received July 18, 2007. Accepted in final form September 14, 2007.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Current and past Epstein-Barr virus infection in risk of initial CNS demyelination
Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility
Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS
Elevated EBNA-1 IgG in MS is associated with genetic MS risk variants